The mechanisms for the hypocholesterolemic action of neomycin were examined in six patients with various levels of plasma total cholesterol and triglycerides. All patients were studied on a metabolic ward. The first period of 6 weeks was for control. Thereafter, neomycin (1.5 g/day) was started, and the patients were readmitted for another 6-week period after 2 to 3 months of treatment with the drug. Cholesterol balance studies showed that neomycin increased fecal excretion of neutral steroids by an average of 45%; the drug also inhibited absorption of exogenous cholesterol by an average of 44%. During treatment with neomycin, the plasma total cholesterol fell by an average of 20%, low density lipoproteins (LDL) fell by 25%, and high density lipoproteins, by 16%. Neomycin did not change plasma triglyceride levels. Turnover of the apoprotein of LDL (apoLDL) was measured following injection of 12S l-apoLDL. Neomycin decreased synthesis of apoLDL by 28%. The decrease in plasma apoLDL level was correlated positively with the decrease in apoLDL synthetic rate. The effect of the drug on clearance of LDL was less constant; four of six patients had an increase in fractional clearance rates of apoLDL, but the change for the whole group was not statistically significant. These data suggest that a decrease in production of LDL is a major factor in the lowering of LDL following inhibition of cholesterol absorption; however, an increase in clearance rates may occur in some patients.
N eomycin is an almost nonabsorbable aminoglycoside antibiotic with a broad spectrum of activity. It also reduces plasma cholesterol in relatively low doses. 1 -2 Most of the cholesterol lowering occurs in low density lipoproteins (LDL). The mechanism by which neomycin lowers LDL has been attributed mainly to a decrease in intestinal absorption of cholesterol. 34 A reduction in cholesterol absorption presumably decreases the quantity of cholesterol transported to the liver with chylomicrons. One response to a decrease in hepatic cholesterol is an increase in cholesterol synthesis. 5 This response, however, is not sufficient to prevent a fall in plasma LDL. The reason for the decrease in LDL levels has not been explained. One possibility is that a fall in hepatic cholesterol concentrations causes an increase in hepatic receptors for LDL which should promote LDL clearance. If this mechanism pertains, a fall in plasma LDL should be reflected by an increase in the fractional catabolic rate (FCR) of LDL. To test this hypothesis, turnover rates of LDL were estimated in six patients before and during treatment with neomycin.
Methods

Patients
Six men were admitted to the Special Diagnostic and Treatment Unit (Metabolic Unit) at the Veterans Administration Medical Center, San Diego, California. The age, body habitus at time of admission, and diagnosis of each patient are presented in Table 1 . At first admission, total cholesterol ranged from 224 to 291 mg/dl. Two patients (Nos. 1 and 5) had plasma cholesterol levels above the 95th percentile for the corresponding age and sex group according to the Lipid Research Clinics Program Prevalence Study. 67 The plasma triglyceride levels ranged from 
Experimental Design
Patients were studied during two periods, each of approximately 6 weeks duration. The first period was for control studies; thereafter, the patients were discharged and started on neomycin, 500 mg orally three times daily with meals. After taking neomycin for 2 to 3 months the patients were readmitted into the metabolic unit for the second 6-week period. All patients were fed a diet of solid food and liquid formula, identical each day, throughout both periods.
The general design of the study was as follows. Plasma lipids and lipoproteins were estimated twice weekly. Cholesterol balance measurements were carried out in five subjects throughout both periods. Intestinal cholesterol absorption was measured in three patients during the second or third week of each period. Turnover of low density lipoprotein apoprotein (apoLDL) was carried out during the last 2 or 3 weeks of each period. All patients tolerated neomycin well and had no significant side effects.
Diets
The diet during hospitalization consisted of mixed solid food and liquid formula containing 40% of calories as fat. The basic composition and pattern of this diet have been described previously in detail. 8 The patients were given three liquid meals and one meal of solid food per day. Calories were divided approximately equally between the feedings. Liquid formulas were given at 8:30 A.M., 1:00 P.M., and 7:00 P.M. and they contained 15% of calories as milk protein, 45% as dextrose, and 40% as fat, mostly in the form of lard. These diets were prepared by Hospital Diet Products, Organon Corporation, Buena Park, California (courtesy of Fred Teixeira). One meal of solid food was given at 11:00 A.M., and it contained dry cereal (corn flakes), nonfat bread, skim milk, added fat, and sugar for coffee. Fat comprised approximately 40% of calories in these meals. Cholesterol intakes ranged between 103 and 124 mg/day. Vitamin and mineral supplements were given daily. Each patient was weighed daily, and caloric intake was adjusted to maintain total body weight at a constant level throughout the control and neomycin periods.
Plasma Lipids and Lipoproteins
Blood for plasma lipid and lipoprotein quantification was obtained twice weekly after a 12-hour fast. Total cholesterol and triglycerides were determined on a Technicon Auto-Analyzer (Model II, Technicon Instruments Corporation, Tarrytown, New York). 910 Concentrations of cholesterol and triglycerides in very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) were estimated as described in the Lipid Research Clinics Manual of Laboratory Operations. 11
Lipoprotein Turnover Studies
Measurements of turnover of apoLDL were performed on the six subjects as previously described. 12 ' 13 After the patients had been on the metabolic diet for 1 to 2 weeks, plasmapheresis was carried out for lipoprotein isolation. LDL (d = 1.025-1.060 g/ml) was isolated from each patient, and the protein moiety was labeled with 125 I by the iodinemonochloride method of McFarlane 14 as modified by Bilheimer et al. 15 Unbound 12S I was removed by dialysis and the labelled LDL was diluted with 5% human serum albumin and sterilized by passage through a 0.22 fim Millipore filter. The degree of lipid labelling was determined by extraction of the labelled LDL with a chloroform/methanol solvent (2M, vol/vol) using the method of Folch et al. 18 The organic phase was evaporated to dryness, and the residual lipid was counted in dry tubes. The mean percentage of counts in the lipid moiety was 4.1% (0.9% to 7.1%). The mean amount of unbound iodine after dialysis was checked by thin-layer chromatography on Gelman ITLC-SG sheets (Gelman Instrument Company, Ann Arbor, Michigan) using 20% trichloroacetic acid containing 0.125% sodium metabisulfite as a chromatography system. The number of counts at the solvent front compared to the total counts present was taken to represent the percentage of 12S I not bound to LDL protein. This amount averaged 0.39% (0.15% to 0.95%). The labelled LDL was injected intravenously; it contained 50-70 /aCi of radioactivity and 2-10 mg of protein. Blood samples were collect-ed at 5,10,15,20,30,and 60 minutes; 3,6,9,12,24, 36, and 48 hours; and daily (fasting) thereafter for 14-21 days. Determinations of radioactivity and concentrations of total cholesterol and triglyceride were made on each plasma sample. Previous studies have shown that little or no 125 I-LDL radioactivity is transferred to other lipoprotein fractions; thus analyses were based on total radioactivity per milliliter of plasma. Lipoprotein lipid and protein quantification was done biweekly throughout the study.
Urine specimens were collected in bottles containing an alkaline preservative 17 and were pooled during the following time intervals after the intravenous injection of 12S I-LDL: 0 time to 1,1-3, 3-6, 6-12, and 12-24 hours and for every 24-hour period thereafter. Values for urinary radioactivity were normalized to a constant creatinine excretion. All radioactivity was determined in a Packard Model 5820 automatic gamma scintillation spectrometer (Packard Instrument Company, Downers Grove, Illinois). The patients received 0.5-0.9 gms of Kl orally in divided doses each day to suppress 125 I uptake by the thyroid. The fractional catabolic rate (FCR) and synthesis rate for apoLDL were determined as previously described. 12 ' 13 Briefly, two exponential components of the die-away curve of plasma radioactivity were fit with the 2-pool Matthews model; 18 the data were used to calculate an FCR for plasma apoLDL. The FCR was measured independently by relating the daily urinary excretion rate of 125 I radioactivity to the 125 I radioactivity in plasma (U/P ratio) as described previously. 13 The synthetic rate for apoLDL was calculated as follows: apo LDL synthesis = (plasma apoLDL concentration) x (plasma volume) x (FCR). Plasma volume was calculated by the isotope-dilution technique from the known injected dose and the intercept of the calculated 2-exponential curve. The concentration of apoLDL was calculated from the mean of the four to six measured values for LDL-cholesterol and the four to six measured ratios of protein-to-cholesterol in each patient's LDL. These measurements were done biweekly throughout the study. LDL protein was determined by a modified method of Lowry et al. 19 as described by Sata et al. 20 
Cholesterol Balance Studies
Cholesterol balance studies were carried out on five patients as described previously. 2122 The periods were relatively long, and the stools generally were combined into 10-14 day pools. In one patient (No. 6) all stools from Period I were combined into a single pool for analysis. Fecal neutral and acidic steroids were isolated separately, and their masses were determined by gas-liquid chromatography (GLC). 2 ' a To correct for losses of neutral steroids, p-sitosterol was given as capsules (225 mg twice daily), 23 and excretion of acidic steroids was corrected for variations in fecal flow by use of chromic oxide. 24 
Cholesterol Absorption
The percentage of cholesterol absorption was measured on three patients by a method previously described by Crouse and Grundy. 25 Briefly, this technique involved feeding 14 C-cholesterol and 3 H B-sitosterol three times daily with formula. Stools were recorded individually for 7 days and the ratio of isotope was measured by liquid-scintillation counting after saponification, hexane extraction, and thin-layer chromatography to isolate the neutral steroid fraction. The percentage of absorption is obtained by comparing the daily ratio of isotope in stools over a 7-day period with the ratio given by mouth.
Results
Plasma Llpids and Llpoprotelns
The mean values for concentrations of plasma total cholesterol and triglyceride (TG) and cholesterol and TG in each of the lipoproteins, VLDL, LDL, and HDL, during control and neomycin treatment are presented in Table 2 . Plasma total cholesterol was decreased in all six patients, and overall, neomycin reduced total cholesterol 20%. Plasma total TG was reduced by neomycin in one subject, but for all six patients neomycin did not change mean plasma TG. Cholesterol in VLDL was decreased by neomycin therapy in two patients, but again mean values of VLDL cholesterol remained unchanged during neomycin treatment. Similarly, neomycin did not significantly alter levels of VLDL-TG except in one subject (No. 1). LDL cholesterol was reduced in five patients by neomycin, and overall, neomycin decreased LDL cholesterol by 25%. Neomycin lowered LDL-TG in two subjects and for all six patients LDL-TG values were reduced 20% by neomycin. HDL cholesterol was significantly decreased by neomycin in three patients, and mean HDL cholesterol fell 16%. HDL-TG levels were lowered by neomycin in two patients and overall, neomycin decreased HDL-TG by 19%. Table 3 shows kinetic parameters for 125 l-apoLDL turnover in six patients during the control and neomycin periods. Neomycin lowered plasma apoLDL concentration in all six subjects with an overall decrease of 25%. Small changes were noted in ratios of protein-to-cholesterol in LDL between control and neomycin periods, but the mean ratio remained unchanged. The mean fractional catabolic rate (FCR) for apoLDL of the six subjects, as calculated from the plasma radioactivity die-away curve, remained unchanged during neomycin therapy. Three individuals (Nos. 1, 3, and 6), however, had a substantial increase in FCR as determined from the die-away curve; another (No. 5) showed an increase based on the U/P ratio. In two patients (Nos. 2 and 4), neither the die-away curve nor the U/P ratio produced a change in FCR. All six subjects showed some de- Period I = control; Period II = neomycin treatment. FCR = fraction of intravascular apoLDL pool metabolized each day, calculated either from the plasma die-away curve (I) or from U:P ratio (II).
ApoLDL Kinetics
'Period II significantly lower than Period I by paired Mest (p < 0.05). tOnly five determinations. crease in production rate of apoLDL on neomycin; and on the average, the drug lowered apoLDL synthesis by 28% (p < 0.05). Thus, the mean percentage of reduction in synthetic rates was similar to the percentage fall in apoLDL levels.
Cholesterol Balance and Absorption
The fecal outputs of neutral, acidic, and total steroids and the values for cholesterol balance in five subjects during the control and neomycin treatment periods are shown in Table 4 . Neomycin enhanced excretion of neutral steroids in four patients; for the five patients studied, neutral steroid output was in-creased significantly (p < 0.005). Bile acid excretion was enhanced in two subjects, but overall, no change was noted in the average of five patients. Fecal total steroid excretion and cholesterol balance were clearly increased during drug therapy in three subjects; for all five, neomycin significantly enhanced the average output of fecal total steroids and net cholesterol balance (p < 0.05). Table 5 shows the percentage of absorption of cholesterol in three patients during the control and neomycin periods. Neomycin significantly decreased the percentage of cholesterol absorbed in each of the three patients (p < 0.01). tPeriod II significantly lower than Period I by paired rtest (p< 0.01).
Discussion
Effects of Neomycin on Cholesterol Metabolism
The major action of neomycin on the metabolism of cholesterol appears to be a reduction in intestinal absorption of cholesterol. Sedaghat et al. 3 reported on the effects of this drug on absorption of cholesterol and fecal excretion of neutral and acidic steroids; they observed a marked decrease in absorption of exogenous cholesterol along with an unabating increase in excretion of fecal neutral steroids. The latter is consistent with reduced absorption of intestinal cholesterol. Increases in fecal acidic steroids, in contrast, were small, inconstant, and transitory. These workers therefore suggested that the primary cause of plasma cholesterol lowering by neomycin is interference with absorption of cholesterol in the intestine. Similar findings were later reported by Miettinen. 4 The present study showed almost identical results. Cholesterol b a i l e e studies demonstrated an increase in fecal neutral steroids that persisted after 3 months of neomycin therapy. A major increase in excretion of bile acids was found only in one patient (No. 3). Measurements of absorption of exogenous cholesterol in three patients confirmed the findings of Sedaghat et al. 3 and Miettinen et al. 4 In our view, therefore, the fundamental action of neomycin on cholesterol metabolism is to block cholesterol absorption. It should also be emphasized that the reduction in the absorption of cholesterol included not only the small amount in the diet but also the much larger amount excreted in the bile. Therefore, the major portion of the increment in neutral steroid excretion must be the result of reduced absorption of endogenous biliary cholesterol.
Despite these findings, neomycin could have other effects within the gastrointestinal tract. The drug alters the bacterial flora of the colon. The usual conversions of the primary bile acids (cholic acid and chenodeoxycholic acid) into the major secondary bile acids (deoxycholic acid and lithocholic acid) are inhibited; as a result, the feces contain only small amounts of the secondary bile acids. Samuel et al. 26 have suggested that elimination of deoxycholate from the enterohepatic circulation may cause a lowering of plasma cholesterol independently of a reduction in cholesterol absorption. This possibility remains to be proven, however. Also, it is well known that inhibition of cholesterol absorption by other agents (e.g., sitosterol and surformer) lowers plasma cholesterol. Recently, Crouse et al. 27 compared the actions of neomycin and other inhibitors of cholesterol absorption on plasma cholesterol levels. This comparison showed that the fall in plasma total cholesterol or LDL cholesterol is proportional to the degree of inhibition of cholesterol absorption, regardless of the agent used. When neomycin was compared to other agents, the lowering of plasma cholesterol was close to that predicted from its effects on cholesterol absorption. This seems to confirm that the primary mechanism of plasma cholesterol reduction by neomycin is the inhibition of cholesterol absorption. Since neomycin generally produces a greater decrease in cholesterol absorption than the other drugs listed above, it was the drug chosen for the current study.
The persistent increase in excretion of fecal total steroids during neomycin therapy indicates that synthesis of cholesterol is enhanced to compensate for that lost in feces. Some of the increment in fecal steroids may reflect a mobilization of cholesterol from tissue pools, 3 but for reasons discussed previously, 4 the magnitude and duration of the increase indicate that most of it was the result of heightened cholesterol synthesis. In most patients given neomycin, however, absorption is blocked to a such degree that losses cannot be replaced exactly by new synthesis. This may partly explain the fall in plasma cholesterol, noted in all of the present patients.
Effects of Neomycin on Metabolism of Llpoprotelns
The plasma concentrations of cholesterol and triglyceride differed among the subjects of the present study. Two patients had elevated plasma cholesterol, and two had increased triglyceride levels. Three had plasma lipids below the 95th percentile limits for the general population. 67 However, the fecal output of neutral steroids was increased in each of the five subjects studied, and the plasma cholesterol was lowered in all six patients. Therefore, neomycin probably had a similar effect in each subject. The fall in plasma cholesterol during treatment with neomycin was due mainly to a decrease in LDL. The mechanisms for this reduction in LDL concentrations, therefore, can be considered. The primary question under consideration was whether neomycin reduced the input of LDL, or enhanced its clearance. To answer this question, we measured turnover of apoLDL before and during treatment with the drug.
Our hypothesis was that the drug should act mainly to promote clearance of LDL. This hypothesis was based on the following reasoning. Inhibition of cholesterol absorption will decrease the quantity of cholesterol returning to liver with chylomicron remnants. The result should be a reduction of hepatocellular cholesterol. Two changes might be expected. A decrease in cholesterol within the liver cell should evoke a compensatory increase in synthesis of cholesterol, a change that was, in fact, noted. The second response might be an increase in cell surface receptors for LDL. A reduction of intracellular cholesterol is known to increase synthesis of LDL receptors in cells grown in tissue culture. If the latter occurs, the clearance of LDL by the liver should have been increased, reflecting an increase in FCR of LDL.
The foundation of this reasoning has recently been reviewed in detail by Packard and Shepherd. 28 Their review, based on several important studies, 29 " 34 provides convincing evidence that an increase in hepatic receptors for LDL is responsible for the fall in cholesterol levels with bile acid sequestrants and ileal bypass surgery. The same mechanisms might be expected to pertain following inhibition of absorption of cholesterol.
Three of our six patients indeed showed an increase in FCR of apoLDL on neomycin when the FCR was calculated by the plasma die-away curve; another had an increase as calculated by the U/P ratio. Two others, however, had no change by either method of calculating FCR. Nonetheless, in those patients in whom an increased FCR was noted, enhanced catabolism of LDL contributed to the fall in their LDL levels. Therefore, we have not ruled out the possibility that an increase in clearance of LDL may be one factor responsible for lowering the LDL by neomycin, at least in some patients. When this occurs, an increase in LDL receptors (apo B/E receptors) most likely is the cause. Before the importance of enhanced clearance of LDL as a contributing factor to LDL lowering can be determined, more pa-tients representing different categories of hyperlipidemia will have to be studied.
In contrast to the inconstant change in FCR, a decrease in production of apoLDL was noted in all patients treated with neomycin. The average reduction in apoLDL production was similar to the mean fall in apoLDL levels. This observation suggests that a fall in production of LDL was the major factor responsible for the decrease in LDL concentrations in the current study.
What are the mechanisms for this decline in LDL production during neomycin therapy? One possibility could be a decrease in hepatic synthesis of apo B. Synthesis of apo B may be linked in some way to intracellular concentrations of cholesterol. A decrease in hepatic cholesterol might produce a corresponding decrease in synthesis of apo B. Factors regulating synthesis of hepatic apo B are not well understood. Recent studies from our laboratory indicate that production of apoLDL in obese patients is increased, and since these patients also have an increase in synthesis of cholesterol, 35 their synthesis of apo B might be accelerated in proportion to the increment in formation of cholesterol.
A decrease in production of apoLDL might arise in other ways. One way could be by an increased clearance of VLDL remnants. Normally a significant fraction of VLDL remnants is converted to LDL, but under certain circumstances an increased fraction of VLDL remnants is removed directly from the circulation. This mechanism appears especially prominent in patients with hypertriglyceridemia. 36 " 39 VLDL remnants also are thought to be removed via apo B/E receptors. 40 Inhibition of cholesterol absorption might lead to an increase in apo B/E receptors, and thereby promote remnant uptake; the result would be a decreased production of apoLDL. Still another way of decreasing production of apoLDL can be visualized, namely, an increase in hepatic B/E receptors. An increase in B/E receptors on the hepatocyte might capture newly secreted particles containing apo B before they enter plasma. In any case, future studies may demonstrate that factors regulating B/E receptors play a critical role in regulating production of LDL as well as its clearance. Support for the concept that LDL production is dependent on the quantity of cholesterol absorbed by the gut is the recent report of Packard et al. 41 that cholesterol feeding to healthy volunteers increases LDL synthesis. The feeding of six eggs per day raised LDL-cholesterol by 40%; at the same time, LDL synthesis was increased by 23%. The FCR of LDL also fell significantly, but only by 10%. Their findings, therefore, are in agreement with ours that the major effect of newly absorbed cholesterol is on the production of LDL, while the influence of LDL clearance is less marked.
The results of Packard et al. 41 also are in accord with our findings on HDL cholesterol levels. With cholesterol feeding, HDL cholesterol rose by 18%; in our study, inhibiting cholesterol absorption with neo-mycin dropped HDL cholesterol by 16%. The mechanisms responsible for these opposing effects are not apparent. One possibility, however, might be considered. Cholesterol in HDL is thought to arise from several sources: 1) from extrahepatic tissues, 2) by transfer of cholesterol ester from other lipoproteins, 4243 and 3) from unesterified cholesterol derived from the surface coat of triglyceride-rich lipoproteins during lipolysis. The latter includes chylomicrons. With high intakes of cholesterol, the cholesterol content of chylomicrons should be increased; during neomycin treatment, it should fall. This variability in cholesterol content of chylomicrons could produce corresponding changes in HDL cholesterol.
The decrease in HDL cholesterol during neomycin treatment raises the question of its usefulness as a lipid-lowering agent in view of the inverse association of HDL cholesterol with coronary heart disease. The ratio of LDL cholesterol to HDL cholesterol, however, was decreased by neomycin therapy from 3.77 to 3.66 indicating that the fall in LDL cholesterol exceeded that in HDL. Therefore, in our view, neomycin is potentially useful as a hypocholesterolemic agent, particularly since side effects produced by small doses of oral neomycin seem minimal. 44 
